Haemonetics Cash from 2010 to 2024

HAE Stock  USD 85.43  0.51  0.60%   
Haemonetics' Cash is increasing over the years with slightly volatile fluctuation. Cash is expected to dwindle to about 138.4 M. Cash is the total amount of money in the form of currency that Haemonetics has in its possession. This includes all bills, coins, and funds in bank accounts. View All Fundamentals
 
Cash  
First Reported
1991-06-30
Previous Quarter
344.4 M
Current Value
299.3 M
Quarterly Volatility
89.5 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Haemonetics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Haemonetics' main balance sheet or income statement drivers, such as Interest Expense of 15.4 M, Total Revenue of 1.4 B or Gross Profit of 710.4 M, as well as many indicators such as Price To Sales Ratio of 4.27, Dividend Yield of 0.0098 or PTB Ratio of 5.13. Haemonetics financial statements analysis is a perfect complement when working with Haemonetics Valuation or Volatility modules.
  
Check out the analysis of Haemonetics Correlation against competitors.
For information on how to trade Haemonetics Stock refer to our How to Trade Haemonetics Stock guide.

Latest Haemonetics' Cash Growth Pattern

Below is the plot of the Cash of Haemonetics over the last few years. Cash refers to the most liquid asset of Haemonetics, which is listed under current asset account on Haemonetics balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from Haemonetics customers. The amounts must be unrestricted with restricted cash listed in a different Haemonetics account. It is the total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts. Haemonetics' Cash historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Haemonetics' overall financial position and show how it may be relating to other accounts over time.
Cash10 Years Trend
Slightly volatile
   Cash   
       Timeline  

Haemonetics Cash Regression Statistics

Arithmetic Mean170,597,651
Geometric Mean134,669,745
Coefficient Of Variation38.33
Mean Deviation44,120,639
Median178,800,000
Standard Deviation65,386,043
Sample Variance4275.3T
Range281.6M
R-Value0.39
Mean Square Error3890.5T
R-Squared0.16
Significance0.15
Slope5,756,566
Total Sum of Squares59854.7T

Haemonetics Cash History

2024138.4 M
2023178.8 M
2022284.5 M
2021259.5 M
2020192.3 M
2019137.3 M
2018169.4 M

Other Fundumenentals of Haemonetics

Haemonetics Cash component correlations

About Haemonetics Financial Statements

Haemonetics stakeholders use historical fundamental indicators, such as Haemonetics' Cash, to determine how well the company is positioned to perform in the future. Although Haemonetics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Haemonetics' assets and liabilities are reflected in the revenues and expenses on Haemonetics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Haemonetics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Cash178.8 M138.4 M
Cash And Short Term Investments178.8 M140.6 M
Cash And Equivalents327.1 M214.1 M
Change In Cash-105.7 M-100.4 M
Free Cash Flow115.5 M121.2 M
Begin Period Cash Flow284.5 M298.7 M
Other Cashflows From Financing Activities-6.8 M-6.5 M
Other Non Cash Items24.4 M20.1 M
Total Cash From Operating Activities181.8 M107 M
Total Cash From Financing Activities38.2 M40.1 M
End Period Cash Flow178.8 M138.4 M
Other Cashflows From Investing Activities-450.8 K-473.3 K
Total Cashflows From Investing Activities-129.4 M-135.9 M
Cash And Cash Equivalents Changes33.2 M34.9 M
Cash Flows Other Operating-18 M-17.1 M
Free Cash Flow Yield 0.03  0.04 
Operating Cash Flow Per Share 3.58  4.18 
Free Cash Flow Per Share 2.28  2.76 
Cash Per Share 3.56  3.42 
Capex To Operating Cash Flow 0.36  0.34 
EV To Operating Cash Flow 27.27  17.85 
EV To Free Cash Flow 42.93  27.02 
Price To Operating Cash Flows Ratio 23.81  17.52 
Price To Free Cash Flows Ratio 37.48  26.52 
Cash Ratio 0.60  0.47 
Cash Conversion Cycle 198.31  139.35 
Operating Cash Flow Sales Ratio 0.14  0.24 
Free Cash Flow Operating Cash Flow Ratio 0.64  0.66 
Cash Flow Coverage Ratios 0.22  0.87 
Price Cash Flow Ratio 23.81  17.52 
Cash Flow To Debt Ratio 0.22  0.87 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Haemonetics is a strong investment it is important to analyze Haemonetics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Haemonetics' future performance. For an informed investment choice regarding Haemonetics Stock, refer to the following important reports:
Check out the analysis of Haemonetics Correlation against competitors.
For information on how to trade Haemonetics Stock refer to our How to Trade Haemonetics Stock guide.
You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Haemonetics. If investors know Haemonetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Haemonetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.375
Earnings Share
2.41
Revenue Per Share
26.77
Quarterly Revenue Growth
0.086
Return On Assets
0.0588
The market value of Haemonetics is measured differently than its book value, which is the value of Haemonetics that is recorded on the company's balance sheet. Investors also form their own opinion of Haemonetics' value that differs from its market value or its book value, called intrinsic value, which is Haemonetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Haemonetics' market value can be influenced by many factors that don't directly affect Haemonetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Haemonetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Haemonetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Haemonetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.